01 / DESIGN
What was studied?
FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease to semaglutide or placebo. The primary outcome combined major kidney events with kidney-related or cardiovascular death.
02 / FINDINGS
What did the researchers report?
The primary outcome occurred less often with semaglutide. The trial stopped early following a prespecified interim analysis, with median follow-up of 3.4 years.
03 / LIMITS
How should it be interpreted?
The result is specific to participants meeting the kidney-function and diabetes criteria. A composite outcome includes different events; it should not be read as proof of reversing kidney disease or as evidence for catalog products.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.